Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.420 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Apple, Amazon, HP And Other Big Losers From Friday
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion. 
Via Benzinga
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket
Gainers 
Via Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
The 5 Top Stocks Cathie Wood Is Buying Now
Cathie Wood's ETFs have performed well following the release of July's CPI report. Recent Cathie Wood stocks include NVTA, TDOC and RBLX. 
Via InvestorPlace
Fate Therapeutics Initiated With Hold Rating - Read Why
Via Benzinga
Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock
Via Benzinga
Expert Ratings for Fate Therapeutics
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: 
Via Benzinga
Recap: Fate Therapeutics Q1 Earnings
Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids. 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock
FATE stock is in focus after Cathie Wood's Ark Invest purchased over 600,000 shares yesterday. This was Ark's first purchase since February. 
Via InvestorPlace
Cathie Wood Scoops Up Over $20M Worth Of Fate Therapeutics Shares, Dumps More Twitter Stock
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm’s exchange-traded funds... 
Via Benzinga
7 Small-Cap Stocks to Buy Before the Bull Market Returns
These small-cap stocks to buy before the bull market returns have underperformed the market, but have immense potential for future gains. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
  
Via Benzinga
7 Cathie Wood Stocks Trading at a Discount Right Now
These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments. 
Via InvestorPlace
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
7 Small-Cap Stocks to Buy in July 2022
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
Upgrades 
Via Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Fate Therapeutics
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Fate Therapeutics: Q4 Earnings Insights
Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Fate Therapeutics's Earnings: A Preview
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Outlook For Fate Therapeutics
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.